Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Diabetes Mellitus HELP
Based on 99,999 articles published since 2007
|||| 37 

These are the 99999 published articles about Diabetes Mellitus that originated from Worldwide during 2007-2017.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. 2017

Hooper, Philip / Boucher, Marie Carole / Cruess, Alan / Dawson, Keith G / Delpero, Walter / Greve, Mark / Kozousek, Vladimir / Lam, Wai-Ching / Maberley, David A L. ·Philip Hooper, London, ON (Chair) (retina and uveitis); Marie Carole Boucher, Montreal, QC (retina and teleophthalmology); Alan Cruess, Halifax, NS (retina); Keith G. Dawson, Vancouver, BC (endocrinology); Walter Delpero, Ottawa, ON (cataract and strabismus); Mark Greve, Edmonton, AB (retina and teleophthalmology); Vladimir Kozousek, Halifax, NS (medical retina); Wai-Ching Lam, Toronto, ON (retina and research); David A.L. Maberley, Vancouver, BC (retina).. Electronic address: cjo@cos-sco.ca. · Philip Hooper, London, ON (Chair) (retina and uveitis); Marie Carole Boucher, Montreal, QC (retina and teleophthalmology); Alan Cruess, Halifax, NS (retina); Keith G. Dawson, Vancouver, BC (endocrinology); Walter Delpero, Ottawa, ON (cataract and strabismus); Mark Greve, Edmonton, AB (retina and teleophthalmology); Vladimir Kozousek, Halifax, NS (medical retina); Wai-Ching Lam, Toronto, ON (retina and research); David A.L. Maberley, Vancouver, BC (retina). ·Can J Ophthalmol · Pubmed #29074014.

ABSTRACT: -- No abstract --

2 Guideline Synopsis of the 2017 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: Management of Type 2 Diabetes Mellitus. 2017

Conlin, Paul R / Colburn, Jeffrey / Aron, David / Pries, Rose Mary / Tschanz, Mark P / Pogach, Leonard. ·From VA Boston Healthcare System, West Roxbury, Massachusetts; San Antonio Military Medical Center, Fort Sam Houston, Texas; Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio; VHA National Center for Health Promotion and Disease Prevention, Durham, North Carolina; San Diego Internal Medicine, San Diego, California; and Veterans Affairs Central Office, Office of Specialty Care Services, Washington, DC. ·Ann Intern Med · Pubmed #29059687.

ABSTRACT: Description: In April 2017, the U.S. Department of Veterans Affairs (VA) and the U.S. Department of Defense (DoD) approved a joint clinical practice guideline for the management of type 2 diabetes mellitus. Methods: The VA/DoD Evidence-Based Practice Work Group convened a joint VA/DoD guideline development effort that included a multidisciplinary panel of practicing clinician stakeholders and conformed to the Institute of Medicine's tenets for trustworthy clinical practice guidelines. The guideline panel developed key questions in collaboration with the ECRI Institute, which systematically searched and evaluated the literature through June 2016, developed an algorithm, and rated recommendations by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Recommendations: This synopsis summarizes key features of the guideline in 7 areas: patient-centered care and shared decision making, glycemic biomarkers, hemoglobin A1c target ranges, individualized treatment plans, outpatient pharmacologic treatment, glucose targets for critically ill patients, and treatment of hospitalized patients.

3 Guideline Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. 2017

Chamberlain, James J / Kalyani, Rita Rastogi / Leal, Sandra / Rhinehart, Andrew S / Shubrook, Jay H / Skolnik, Neil / Herman, William H. ·From St. Mark's Hospital and St. Mark's Diabetes Center, Salt Lake City, Utah; Johns Hopkins University, Baltimore, Maryland; SinfoníaRx, Tucson, Arizona; Glytec, Marco Island, Florida; Touro University College of Osteopathic Medicine, Vallejo, California; Abington Memorial Hospital, Jenkintown, Pennsylvania; and University of Michigan, Ann Arbor, Michigan. ·Ann Intern Med · Pubmed #28892816.

ABSTRACT: Description: The American Diabetes Association (ADA) annually updates Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes. Methods: For the 2017 Standards of Care, the ADA Professional Practice Committee did MEDLINE searches from 1 January 2016 to November 2016 to add, clarify, or revise recommendations on the basis of new evidence. The committee rated the recommendations as A, B, or C, depending on the quality of evidence, or E for expert consensus or clinical experience. The Standards of Care were reviewed and approved by the Executive Committee of the ADA Board of Directors, which includes health care professionals, scientists, and laypersons. Feedback from the larger clinical community informed revisions. Recommendation: This synopsis focuses on recommendations from the 2017 Standards of Care about monitoring and pharmacologic approaches to glycemic management for type 1 diabetes.

4 Guideline [2016 European guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts. Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation]. 2017

Piepoli, Massimo F / Hoes, Arno W / Agewall, Stefan / Albus, Christian / Brotons, Carlos / Catapano, Alberico L / Cooney, Marie-Therese / Corrà, Ugo / Cosyns, Bernard / Deaton, Christi / Graham, Ian / Hall, Michael Stephen / Hobbs, F D Richard / Løchen, Maja-Lisa / Löllgen, Herbert / Marques-Vidal, Pedro / Perk, Joep / Prescott, Eva / Redon, Josep / Richter, Dimitrios J / Sattar, Naveed / Smulders, Yvo / Tiberi, Monica / van der Worp, H Bart / van Dis, Ineke / Verschuren, W M Monique. · · European Society of Cardiology (ESC). · International Society of Behavioural Medicine (ISBM). · WONCA Europe. · European Atherosclerosis Society (EAS). · International Diabetes Federation European Region (IDF Europe). · International Federation of Sport Medicine (FIMS). · European Society of Hypertension (ESH). · European Association for the Study of Diabetes (EASD). · European Stroke Organisation (ESO). · European Heart Network (EHN). ·G Ital Cardiol (Rome) · Pubmed #28714997.

ABSTRACT: -- No abstract --

5 Guideline Polish Forum for Prevention Guidelines on Diabetes: update 2017. 2017

Małecki, Maciej / Kozek, Elżbieta / Zozulińska-Ziółkiewicz, Dorota / Kopeć, Grzegorz / Knap, Klaudia / Sarnecka, Agnieszka / Podolec, Jakub / Pająk, Andrzej / Zdrojewski, Tomasz / Czarnecka, Danuta / Jankowski, Piotr / Nowicka, Grażyna / Windak, Adam / Stańczyk, Jerzy / Undas, Anetta / Członkowska, Anna / Niewada, Maciej / Podolec, Piotr. · · Department of Cardiac and Vascular Diseases, Institute of Cardiology, Jagiellonian University Medical College at John Paul II Hospital, Kraków. ppodolec@interia.pl. ·Kardiol Pol · Pubmed #28707289.

ABSTRACT: -- No abstract --

6 Guideline AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE. 2017

Cobin, Rhoda H / Goodman, Neil F / Anonymous4100913. · ·Endocr Pract · Pubmed #28703650.

ABSTRACT: EXECUTIVE SUMMARY This American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) Position Statement is designed to update the previous menopause clinical practice guidelines published in 2011 but does not replace them. The current document reviews new clinical trials published since then as well as new information regarding possible risks and benefits of therapies available for the treatment of menopausal symptoms. AACE reinforces the recommendations made in its previous guidelines and provides additional recommendations on the basis of new data. A summary regarding this position statement is listed below: New information available from randomized clinical trials and epidemiologic studies reported after 2011 was critically reviewed. No previous recommendations from the 2011 menopause clinical practice guidelines have been reversed or changed. Newer information enhances AACE's guidance for the use of hormone therapy in different subsets of women. Newer information helps to support the use of various types of estrogens, selective estrogen-receptor modulators (SERMs), and progesterone, as well as the route of delivery. Newer information supports the previous recommendation against the use of bioidentical hormones. The use of nonhormonal therapies for the symptomatic relief of menopausal symptoms is supported. Newer information enhances AACE's guidance for the use of hormone therapy in different subsets of women. Newer information helps to support the use of various types of estrogens, SERMs, and progesterone, as well as the route of delivery. Newer information supports the previous recommendation against the use of bioidentical hormones. The use of nonhormonal therapies for the symptomatic relief of menopausal symptoms is supported. New recommendations in this position statement include: 1. RECOMMENDATION: the use of menopausal hormone therapy in symptomatic postmenopausal women should be based on consideration of all risk factors for cardiovascular disease, age, and time from menopause. 2. RECOMMENDATION: the use of transdermal as compared with oral estrogen preparations may be considered less likely to produce thrombotic risk and perhaps the risk of stroke and coronary artery disease. 3. RECOMMENDATION: when the use of progesterone is necessary, micronized progesterone is considered the safer alternative. 4. RECOMMENDATION: in symptomatic menopausal women who are at significant risk from the use of hormone replacement therapy, the use of selective serotonin re-uptake inhibitors and possibly other nonhormonal agents may offer significant symptom relief. 5. RECOMMENDATION: AACE does not recommend use of bioidentical hormone therapy. 6. RECOMMENDATION: AACE fully supports the recommendations of the Comité de l'Évolution des Pratiques en Oncologie regarding the management of menopause in women with breast cancer. 7. RECOMMENDATION: HRT is not recommended for the prevention of diabetes. 8. RECOMMENDATION: In women with previously diagnosed diabetes, the use of HRT should be individualized, taking in to account age, metabolic, and cardiovascular risk factors. ABBREVIATIONS: AACE = American Association of Clinical Endocrinologists; ACE = American College of Endocrinology; BMI = body mass index; CAC = coronary artery calcification; CEE = conjugated equine estrogen; CEPO = Comité de l'Évolution des Pratiques en Oncologie; CAD = coronary artery disease; CIMT = carotid intima media thickness; CVD = cardiovascular disease; FDA = Food and Drug Administration; HDL = high-density lipoprotein; HRT = hormone replacement therapy; HT = hypertension; KEEPS = Kronos Early Estrogen Prevention Study; LDL = low-density lipoprotein; MBS = metabolic syndrome; MPA = medroxyprogesterone acetate; RR = relative risk; SERM = selective estrogen-receptor modulator; SSRI = selective serotonin re-uptake inhibitor; VTE = venous thrombo-embolism; WHI = Women's Health Initiative.

7 Guideline A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety. 2017

Fitchett, David / Cheng, Alice / Connelly, Kim / Goldenberg, Ronald / Goodman, Shaun G / Leiter, Lawrence A / Lonn, Eva / Paty, Breay / Poirier, Paul / Stone, James / Thompson, David / Yale, Jean-Francois / Mancini, G B John. ·Division of Cardiology, St Michael's Hospital, Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, University of Toronto, Toronto, Ontario, Canada. Electronic address: fitchettd@smh.ca. · Division of Endocrinology and Metabolism, University of Toronto, Toronto, Ontario, Canada. · Division of Cardiology, St Michael's Hospital, Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, University of Toronto, Toronto, Ontario, Canada. · Endocrinology and Metabolism, North York General Hospital and LMC Diabetes and Endocrinology, Toronto, Ontario, Canada. · Division of Endocrinology and Metabolism, Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, University of Toronto, Toronto, Ontario, Canada. · Population Health Research Institute and Department of Medicine, McMaster University, Hamilton, Ontario, Canada. · Division of Endocrinology, University of British Columbia, Vancouver, British Columbia, Canada. · Heart and Lung Institute, Laval University, Québec City, Québec, Canada. · Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. · Division of Endocrinology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada. · Division of Endocrinology, McGill University Health Centre, McGill University, Montreal, Canada. ·Can J Cardiol · Pubmed #28668144.

ABSTRACT: Patients with type 2 diabetes continue to have a high residual risk for cardiovascular events despite intensive risk factor modification. Recent clinical trials have shown that the antihyperglycemic agents empagliflozin and liraglutide reduce cardiovascular events. Other drugs have been shown to have cardiovascular safety. With glucose-lowering agents proven to reduce adverse cardiovascular outcomes, many cardiologists have begun to prescribe or recommend glucose-lowering agents. Other cardiologists are not yet comfortable with this role because they are not accustomed to initiating these drugs. This document provides updated details of glucose-lowering agents associated with either proven cardiovascular benefit or safety, to help cardiologists to safely prescribe and monitor their patients with diabetes.

8 Guideline Practice Bulletin No. 180: Gestational Diabetes Mellitus. 2017

Anonymous5490911. · ·Obstet Gynecol · Pubmed #28644336.

ABSTRACT: Gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy. However, debate continues to surround the diagnosis and treatment of GDM despite several recent large-scale studies addressing these issues. The purposes of this document are the following: 1) provide a brief overview of the understanding of GDM, 2) review management guidelines that have been validated by appropriately conducted clinical research, and 3) identify gaps in current knowledge toward which future research can be directed.

9 Guideline Practice Bulletin No. 180 Summary: Gestational Diabetes Mellitus. 2017

Anonymous5430911. · ·Obstet Gynecol · Pubmed #28644329.

ABSTRACT: GESTATIONAL DIABETES MELLITUS: Gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy. However, debate continues to surround the diagnosis and treatment of GDM despite several recent large-scale studies addressing these issues. The purposes of this document are the following: 1) provide a brief overview of the understanding of GDM, 2) review management guidelines that have been validated by appropriately conducted clinical research, and 3) identify gaps in current knowledge toward which future research can be directed.

10 Guideline Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease. 2017

Gale, R / Scanlon, P H / Evans, M / Ghanchi, F / Yang, Y / Silvestri, G / Freeman, M / Maisey, A / Napier, J. ·The Action on DMO group, UK.; The York Hospital, York, UK. · The Action on DMO group, UK.; Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK. · The Action on DMO group, UK.; University Hospital, Llandough, Cardiff, UK. · The Action on DMO group, UK.; Bradford Teaching Hospitals, Bradford, UK. · The Action on DMO group, UK.; The Royal Wolverhampton NHS Trust, Wolverhampton, UK. · The Action on DMO group, UK.; Belfast Health & Social Care Trust, Belfast, UK. · The Action on DMO group, UK.; Royal Hallamshire Hospital, Sheffield, UK. · The Action on DMO group, UK.; Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff, UK. · The Action on DMO group, UK.; Bayer, Reading, UK. ·Eye (Lond) · Pubmed #28490797.

ABSTRACT: This paper identifies best practice recommendations for managing diabetes and sight-threatening diabetic eye disease. The authors provide an update for ophthalmologists and allied healthcare professionals on key aspects of diabetes management, supported by a review of the pertinent literature, and recommend practice principles for optimal patient management in treating visual impairment due to diabetic eye disease. In people with diabetes, early optimal glycaemic control reduces the long-term risk of both microvascular and macrovascular complications. The authors propose more can and should be done to maximise metabolic control, promote appropriate behavioural modifications and encourage timely treatment intensification when indicated to ameliorate diabetes-related complications. All people with diabetes should be screened for sight-threatening diabetic retinopathy promptly and regularly. It is shown that attitudes towards treatment adherence in diabetic macular oedema appear to mirror patients' views and health behaviours towards the management of their own diabetes. Awareness of diabetic macular oedema remains low among people with diabetes, who need access to education early in their disease about how to manage their diabetes to delay progression and possibly avoid eye-related complications. Ophthalmologists and allied healthcare professionals play a vital role in multidisciplinary diabetes management and establishment of dedicated diabetic macular oedema clinics is proposed. A broader understanding of the role of the diabetes specialist nurse may strengthen the case for comprehensive integrated care in ophthalmic practice. The recommendations are based on round table presentations and discussions held in London, UK, September 2016.

11 Guideline Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). 2017

Cianferotti, Luisella / Bertoldo, Francesco / Bischoff-Ferrari, Heike A / Bruyere, Olivier / Cooper, Cyrus / Cutolo, Maurizio / Kanis, John A / Kaufman, Jean-Marc / Reginster, Jean-Yves / Rizzoli, Rene / Brandi, Maria Luisa. ·Bone Metabolic Diseases Unit, Department of Surgery and Translational Medicine, University Hospital of Florence and University of Florence, Florence, Italy. · Department of Medicine, University of Verona, Verona, Italy. · Department of Geriatrics and Aging Research, University Hospital Zurich and University of Zurich, Zurich, Switzerland. · Epidemiology and Public Health, University of Liege, CHU Sart Tilman, Liege, 4000, Belgium. · MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, Hants, UK. · Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy. · Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK.; Institute for Health and Aging, Catholic University of Australia, Melbourne, VIC, Australia. · Department of Endocrinology and Unit for Osteoporosis and Metabolic Bone Diseases, Ghent University Hospital, Ghent, Belgium. · Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium. · Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland. · Bone Metabolic Diseases Unit, Department of Surgery and Translational Medicine, University Hospital of Florence and University of Florence, Florence, Italy. marialuisa.brandi@unifi.it. ·Endocrine · Pubmed #28390010.

ABSTRACT: INTRODUCTION: Optimal vitamin D status promotes skeletal health and is recommended with specific treatment in individuals at high risk for fragility fractures. A growing body of literature has provided indirect and some direct evidence for possible extraskeletal vitamin D-related effects. PURPOSE AND METHODS: Members of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis have reviewed the main evidence for possible proven benefits of vitamin D supplementation in adults at risk of or with overt chronic extra-skeletal diseases, providing recommendations and guidelines for future studies in this field. RESULTS AND CONCLUSIONS: Robust mechanistic evidence is available from in vitro studies and in vivo animal studies, usually employing cholecalciferol, calcidiol or calcitriol in pharmacologic rather than physiologic doses. Although many cross-sectional and prospective association studies in humans have shown that low 25-hydroxyvitamin D levels (i.e., <50 nmol/L) are consistently associated with chronic diseases, further strengthened by a dose-response relationship, several meta-analyses of clinical trials have shown contradictory results. Overall, large randomized controlled trials with sufficient doses of vitamin D are missing, and available small to moderate-size trials often included people with baseline levels of serum 25-hydroxyvitamin D levels >50 nmol/L, did not simultaneously assess multiple outcomes, and did not report overall safety (e.g., falls). Thus, no recommendations can be made to date for the use of vitamin D supplementation in general, parental compounds, or non-hypercalcemic vitamin D analogs in the prevention and treatment of extra-skeletal chronic diseases. Moreover, attainment of serum 25-hydroxyvitamin D levels well above the threshold desired for bone health cannot be recommended based on current evidence, since safety has yet to be confirmed. Finally, the promising findings from mechanistic studies, large cohort studies, and small clinical trials obtained for autoimmune diseases (including type 1 diabetes, multiple sclerosis, and systemic lupus erythematosus), cardiovascular disorders, and overall reduction in mortality require further confirmation.

12 Guideline Pharmacologic Therapy for Type 2 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. 2017

Chamberlain, James J / Herman, William H / Leal, Sandra / Rhinehart, Andrew S / Shubrook, Jay H / Skolnik, Neil / Kalyani, Rita Rastogi. ·From St. Mark's Hospital and St. Mark's Diabetes Center, Salt Lake City, Utah; University of Michigan, Ann Arbor, Michigan; SinfoníaRx, Tucson, Arizona Glytec, Greenville, South Carolina; Touro University College of Osteopathic Medicine, Vallejo, California; Abington-Jefferson Health, Jenkintown, Pennsylvania; and Johns Hopkins University, Baltimore, Maryland. ·Ann Intern Med · Pubmed #28288484.

ABSTRACT: Description: The American Diabetes Association (ADA) annually updates the Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes. Methods: For the 2017 Standards, the ADA Professional Practice Committee updated previous MEDLINE searches performed from 1 January 2016 to November 2016 to add, clarify, or revise recommendations based on new evidence. The committee rates the recommendations as A, B, or C, depending on the quality of evidence, or E for expert consensus or clinical experience. The Standards were reviewed and approved by the Executive Committee of the ADA Board of Directors, which includes health care professionals, scientists, and laypersons. Feedback from the larger clinical community informed revisions. Recommendations: This synopsis focuses on recommendations from the 2017 Standards about pharmacologic approaches to glycemic treatment of type 2 diabetes.

13 Guideline Clinical worthlessness of genetic prediction of common forms of diabetes mellitus and related chronic complications: A position statement of the Italian Society of Diabetology. 2017

Buzzetti, R / Prudente, S / Copetti, M / Dauriz, M / Zampetti, S / Garofolo, M / Penno, G / Trischitta, V. ·Department of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy; UOC Diabetology, Polo Pontino, "Sapienza" University of Rome, Rome, Italy. · Mendel Laboratory, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. · Unit of Biostatistics, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. · Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona School of Medicine and Hospital Trust of Verona, Verona, Italy. · Section of Diabetes and Metabolic Disease, Department of Clinical and Experimental Medicine, University of Pisa and Azienda Ospedaliero Universitaria Pisana, Pisa, Italy. · Department of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy; Mendel Laboratory, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; Research Unit of Diabetes and Endocrine Diseases, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. Electronic address: vincenzo.trischitta@uniroma1.it. ·Nutr Metab Cardiovasc Dis · Pubmed #28063875.

ABSTRACT: AIM: We are currently facing several attempts aimed at marketing genetic data for predicting multifactorial diseases, among which diabetes mellitus is one of the more prevalent. The present document primarily aims at providing to practicing physicians a summary of available data regarding the role of genetic information in predicting diabetes and its chronic complications. DATA SYNTHESIS: Firstly, general information about characteristics and performance of risk prediction tools will be presented in order to help clinicians to get acquainted with basic methodological information related to the subject at issue. Then, as far as type 1 diabetes is concerned, available data indicate that genetic information and counseling may be useful only in families with many affected individuals. However, since no disease prevention is possible, the utility of predicting this form of diabetes is at question. In the case of type 2 diabetes, available data really question the utility of adding genetic information on top of well performing, easy available and inexpensive non-genetic markers. Finally, the possibility of using the few available genetic data on diabetic complications for improving our ability to predict them will also be presented and discussed. For cardiovascular complication, the addition of genetic information to models based on clinical features does not translate in a substantial improvement in risk discrimination. For all other diabetic complications genetic information are currently very poor and cannot, therefore, be used for improving risk stratification. CONCLUSIONS: In all, nowadays the use of genetic testing for predicting diabetes and its chronic complications is definitively of little value in clinical practice.

14 Guideline Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians. 2017

Qaseem, Amir / Barry, Michael J / Humphrey, Linda L / Forciea, Mary Ann / Anonymous5420942. ·From American College of Physicians and University of Pennsylvania Health System, Philadelphia, Pennsylvania; Massachusetts General Hospital, Boston, Massachusetts; and Oregon Health and Science University, Portland, Oregon. · ·Ann Intern Med · Pubmed #28055075.

ABSTRACT: Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on oral pharmacologic treatment of type 2 diabetes in adults. This guideline serves as an update to the 2012 ACP guideline on the same topic. This guideline is endorsed by the American Academy of Family Physicians. Methods: This guideline is based on a systematic review of randomized, controlled trials and observational studies published through December 2015 on the comparative effectiveness of oral medications for type 2 diabetes. Evaluated interventions included metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Study quality was assessed, data were extracted, and results were summarized qualitatively on the basis of the totality of evidence identified by using several databases. Evaluated outcomes included intermediate outcomes of hemoglobin A1c, weight, systolic blood pressure, and heart rate; all-cause mortality; cardiovascular and cerebrovascular morbidity and mortality; retinopathy, nephropathy, and neuropathy; and harms. This guideline grades the recommendations by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians, and the target patient population includes adults with type 2 diabetes. Recommendation 1: ACP recommends that clinicians prescribe metformin to patients with type 2 diabetes when pharmacologic therapy is needed to improve glycemic control. (Grade: strong recommendation; moderate-quality evidence). Recommendation 2: ACP recommends that clinicians consider adding either a sulfonylurea, a thiazolidinedione, an SGLT-2 inhibitor, or a DPP-4 inhibitor to metformin to improve glycemic control when a second oral therapy is considered. (Grade: weak recommendation; moderate-quality evidence.) ACP recommends that clinicians and patients select among medications after discussing benefits, adverse effects, and costs.

15 Guideline Controversial issues in CKD clinical practice: position statement of the CKD-treatment working group of the Italian Society of Nephrology. 2017

Bellizzi, Vincenzo / Conte, Giuseppe / Borrelli, Silvio / Cupisti, Adamasco / De Nicola, Luca / Di Iorio, Biagio R / Cabiddu, Gianfranca / Mandreoli, Marcora / Paoletti, Ernesto / Piccoli, Giorgina B / Quintaliani, Giuseppe / Ravera, Maura / Santoro, Domenico / Torraca, Serena / Minutolo, Roberto / Anonymous6920879. ·Division of Nephrology, Dialysis and Transplantation, Nephrology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Via San Leonardo, 84131, Salerno, Italy. vincenzo.bellizzi@tin.it. · Nephrology Division, Second University of Naples, Naples, Italy. · Dept. of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. · Nephrology Unit, Landolfi Hospital, Solofra, AV, Italy. · Nephrology Division, Brotzu Hospital, Cagliari, Italy. · Nephrology and Dialysis Unit, Ospedale S. Maria della Scaletta, Imola, BO, Italy. · Nephrology Unit, University of Genoa and IRCCS A.O.U. San Martino IST, Genoa, Italy. · Dept. of Clinical and Biological Sciences, University of Torino, Torino, Italy.; Nephrologie, CH Le Mans, Le Mans, France. · O. U. Nephrology, Dialysis and Transplantation, Santa Maria della Misericordia Hospital, Perugia, Italy. · Dept. of Internal Medicine, University of Messina, Messina, Italy. · Division of Nephrology, Dialysis and Transplantation, Nephrology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Via San Leonardo, 84131, Salerno, Italy. · ·J Nephrol · Pubmed #27568307.

ABSTRACT: This position paper of the study group "Conservative treatment of Chronic Kidney Disease-CKD" of the Italian Society of Nephrology addresses major practical, unresolved, issues related to the conservative treatment of chronic renal disease. Specifically, controversial topics from everyday clinical nephrology practice which cannot find a clear, definitive answer in the current literature or in nephrology guidelines are discussed. The paper reports the point of view of the study group. Concise and practical advice is given on several common issues: renal biopsy in diabetes; dual blockade of the renin-angiotensin-aldosterone system (RAAS); management of iron deficiency; low protein diet; dietary salt intake; bicarbonate supplementation; treatment of obesity; the choice of conservative therapy vs. dialysis. For each topic synthetic statements, guideline-style, are reported.

16 Guideline 7th Brazilian Guideline of Arterial Hypertension: Chapter 8 - Hypertension and Associated Clinical Conditions 2016

Malachias, M V B / Amodeo, C / Paula, R B / Cordeiro, A C / Magalhães, L B N C / Bodanese, L C. · ·Arq Bras Cardiol · Pubmed #27819387.

ABSTRACT: -- No abstract --

17 Guideline Practice Bulletin No. 173 Summary: Fetal Macrosomia. 2016

Anonymous12190885. · ·Obstet Gynecol · Pubmed #27776066.

ABSTRACT: Suspected fetal macrosomia is encountered commonly in obstetric practice. As birth weight increases, the likelihood of labor abnormalities, shoulder dystocia, birth trauma, and permanent injury to the neonate increases. The purpose of this document is to quantify those risks, address the accuracy and limitations of methods for estimating fetal weight, and suggest clinical management for a pregnancy with suspected fetal macrosomia.

18 Guideline 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. 2016

Anderson, Todd J / Grégoire, Jean / Pearson, Glen J / Barry, Arden R / Couture, Patrick / Dawes, Martin / Francis, Gordon A / Genest, Jacques / Grover, Steven / Gupta, Milan / Hegele, Robert A / Lau, David C / Leiter, Lawrence A / Lonn, Eva / Mancini, G B John / McPherson, Ruth / Ngui, Daniel / Poirier, Paul / Sievenpiper, John L / Stone, James A / Thanassoulis, George / Ward, Richard. ·Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address: todd.anderson@ahs.ca. · Institut de Cardiologie de Montréal, Université de Montréal, Montréal, Québec, Canada. · Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada. · Chilliwack General Hospital, Chilliwack, British Columbia, Canada. · Centre Hospitalier de l'Université Laval, Laval, Québec, Canada. · University of British Columbia, Vancouver, British Columbia, Canada. · St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. · McGill University Health Centre, Montréal, Québec, Canada. · Montréal General Hospital and McGill University, Montréal, Québec, Canada. · McMaster University, Hamilton, Ontario, Canada; St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. · Robarts Research Institute, London, Ontario, Canada. · Julia MacFarlane Diabetes Research Centre, Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. · St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. · Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada. · University of Ottawa Heart Institute, Ottawa, Ontario, Canada. · Institut Universitaire de cardiologie et de Pneumologie de Québec, Québec City, Québec, Canada. · Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. · Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada. ·Can J Cardiol · Pubmed #27712954.

ABSTRACT: Since the publication of the 2012 guidelines new literature has emerged to inform decision-making. The 2016 guidelines primary panel selected a number of clinically relevant questions and has produced updated recommendations, on the basis of important new findings. In subjects with clinical atherosclerosis, abdominal aortic aneurysm, most subjects with diabetes or chronic kidney disease, and those with low-density lipoprotein cholesterol ≥ 5 mmol/L, statin therapy is recommended. For all others, there is an emphasis on risk assessment linked to lipid determination to optimize decision-making. We have recommended nonfasting lipid determination as a suitable alternative to fasting levels. Risk assessment and lipid determination should be considered in individuals older than 40 years of age or in those at increased risk regardless of age. Pharmacotherapy is generally not indicated for those at low Framingham Risk Score (FRS; <10%). A wider range of patients are now eligible for statin therapy in the FRS intermediate risk category (10%-19%) and in those with a high FRS (> 20%). Despite the controversy, we continue to advocate for low-density lipoprotein cholesterol targets for subjects who start therapy. Detailed recommendations are also presented for health behaviour modification that is indicated in all subjects. Finally, recommendation for the use of nonstatin medications is provided. Shared decision-making is vital because there are many areas in which clinical trials do not fully inform practice. The guidelines are meant to be a platform for meaningful conversation between patient and care provider so that individual decisions can be made for risk screening, assessment, and treatment.

19 Guideline Diabetes in Pregnancy. 2016

Berger, Howard / Gagnon, Robert / Sermer, Mathew / Basso, Melanie / Bos, Hayley / Brown, Richard N / Bujold, Emmanuel / Cooper, Stephanie L / Gagnon, Robert / Gouin, Katy / McLeod, N Lynne / Menticoglou, Savas M / Mundle, William R / Roggensack, Anne / Sanderson, Frank L / Walsh, Jennifer D. ·Toronto ON. · Montreal QC.; Montreal QC. · Vancouver BC. · Victoria BC. · Beaconsfield QC. · Quebec QC. · Calgary AB. · · Halifax NS. · Winnipeg MB. · Windsor ON. · Saint John NL. · Rothesay NB. ·J Obstet Gynaecol Can · Pubmed #27591352.

ABSTRACT: OBJECTIVE: This guideline reviews the evidence relating to the diagnosis and obstetrical management of diabetes in pregnancy. OUTCOMES: The outcomes evaluated were short- and long-term maternal outcomes, including preeclampsia, Caesarean section, future diabetes, and other cardiovascular complications, and fetal outcomes, including congenital anomalies, stillbirth, macrosomia, birth trauma, hypoglycemia, and long-term effects. EVIDENCE: Published literature was retrieved through searches of PubMed and the Cochrane Library using appropriate controlled vocabulary (MeSH terms "diabetes" and "pregnancy"). Where appropriate, results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. There were no date limits, but results were limited to English or French language materials. VALUES: The quality of evidence was rated using the criteria described in the Report of the Canadian Task Force on Preventive Health Care (Table 1). SUMMARY STATEMENTS: Recommendations It is recognized that the use of different diagnostic thresholds for the "preferred" and "alternative" strategies could cause confusion in certain settings. Despite this, the committee has identified the importance of remaining aligned with the current Canadian Diabetes Association 2013 guidelines as being a priority. It is thus recommended that each care centre strategically align with 1 of the 2 strategies and implement protocols to ensure consistent and uniform reporting of test results.

20 Guideline Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. 2016

Peters, Anne L / Ahmann, Andrew J / Battelino, Tadej / Evert, Alison / Hirsch, Irl B / Murad, M Hassan / Winter, William E / Wolpert, Howard. ·Keck School of Medicine (A.L.P.), University of Southern California, Los Angeles, California 90033; Harold Schnitzer Diabetes Health Center (A.J.A.), Oregon Health & Science University, Portland, Oregon 97239; Department of Medicine (T.B.), University of Ljubljana and University Children's Hospital, 1104 Ljubljana, Slovenia; Endocrine and Diabetes Care Center (A.E., I.B.H.), University of Washington Medical Center, Seattle, Washington 98195; Mayo Clinic Evidence-based Practice Center (M.H.M.), Rochester, Minnesota 55905; UF Diabetes Institute (W.E.W.), University of Florida, Gainesville, Florida 32611; and Joslin Diabetes Center (H.W.), Harvard Medical School, Boston, Massachusetts 02115. ·J Clin Endocrinol Metab · Pubmed #27588440.

ABSTRACT: OBJECTIVE: To formulate clinical practice guidelines for the use of continuous glucose monitoring and continuous subcutaneous insulin infusion in adults with diabetes. PARTICIPANTS: The participants include an Endocrine Society-appointed Task Force of seven experts, a methodologist, and a medical writer. The American Association for Clinical Chemistry, the American Association of Diabetes Educators, and the European Society of Endocrinology co-sponsored this guideline. EVIDENCE: The Task Force developed this evidence-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned one systematic review and used the best available evidence from other published systematic reviews and individual studies. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of the Endocrine Society, the American Association for Clinical Chemistry, the American Association of Diabetes Educators, and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. CONCLUSIONS: Continuous subcutaneous insulin infusion and continuous glucose monitoring have an important role in the treatment of diabetes. Data from randomized controlled trials are limited on the use of medical devices, but existing studies support the use of diabetes technology for a wide variety of indications. This guideline presents a review of the literature and practice recommendations for appropriate device use.

21 Guideline USPSTF update: Screening for abnormal blood glucose, diabetes. 2016

Campos-Outcalt, Doug. ·Medical Director, Mercy Care Plan, Phoenix, AZ, USA. Email: campos-outcaltd@mercycareplan.com. ·J Fam Pract · Pubmed #27565101.

ABSTRACT: Screen all adults, ages 40 to 70 years, who are overweight or obese. Consider screening younger patients who have specific personal or family risk factors.

22 Guideline Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults. 2016

Aschner, Pablo M / Muñoz, Oscar Mauricio / Girón, Diana / García, Olga Milena / Fernández-Ávila, Daniel Gerardo / Casas, Luz Ángela / Bohórquez, Luisa Fernanda / Arango T, Clara María / Carvajal, Liliana / Ramírez, Doris Amanda / Sarmiento, Juan Guillermo / Colon, Cristian Alejandro / Correa G, Néstor Fabián / Alarcón R, Pilar / Bustamante S, Álvaro Andrés. ·Hospital Universitario San Ignacio, Bogota, Colombia; Pontificia Universidad Javeriana, Bogota, Colombia; Asociación Colombiana de Diabetes, Bogota, Colombia. · Hospital Universitario San Ignacio, Bogota, Colombia; Pontificia Universidad Javeriana, Bogota, Colombia. · Departamento de Epidemiología y Bioestadística. Pontificia Universidad Javeriana, Bogota, Colombia. · Asociación Colombiana de Endocrinología, Universidad del Valle, Cali, Colombia. · Federación diabetológica Colombiana, Bogota, Colombia; Universidad Nacional de Colombia, Bogota, Colombia. · Universidad de Antioquia, Medellin, Colombia. · Asociación Colombiana de Diabetes, Bogota, Colombia. · Universidad Nacional de Colombia, Bogota, Colombia. ·Colomb Med (Cali) · Pubmed #27546934.

ABSTRACT: In Colombia, diabetes mellitus is a public health program for those responsible for creating and implementing strategies for prevention, diagnosis, treatment, and follow-up that are applicable at all care levels, with the objective of establishing early and sustained control of diabetes. A clinical practice guide has been developed following the broad outline of the methodological guide from the Ministry of Health and Social Welfare, with the aim of systematically gathering scientific evidence and formulating recommendations using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology. The current document presents in summary form the results of this process, including the recommendations and the considerations taken into account in formulating them. In general terms, what is proposed here is a screening process using the Finnish Diabetes Risk Score questionnaire adapted to the Colombian population, which enables early diagnosis of the illness, and an algorithm for determining initial treatment that can be generalized to most patients with diabetes mellitus type 2 and that is simple to apply in a primary care context. In addition, several recommendations have been made to scale up pharmacological treatment in those patients that do not achieve the objectives or fail to maintain them during initial treatment. These recommendations also take into account the evolution of weight and the individualization of glycemic control goals for special populations. Finally, recommendations have been made for opportune detection of micro- and macrovascular complications of diabetes.

23 Guideline [CROATIAN GUIDELINES FOR THE PHARMACOTHERAPY OF TYPE 2 DIABETES]. 2016

Rahelić, Dario / Altabas, Velimir / Bakula, Miro / Balić, Stjepan / Balint, Ines / Marković, Biserka Bergman / Bicanić, Nenad / Bjelinski, Igor / Bozikov, Velimir / Varzić, Silvija Canecki / Car, Nikica / Berković, Maja Cigrovski / Orlić, Zeljka Crncevic / Deskin, Marin / Sunić, Ema Drvodelić / Tomić, Nives Gojo / Goldoni, Vesna / Gradiser, Marina / Mahecić, Davorka Herman / Balen, Marica Jandrić / Erzen, Dubravka Jurisić / Majanović, Sanja Klobucar / Kokić', Slaven / Krnic, Mladen / Kruljac, Ivan / Liberati-Cizmek, Ana-Marija / Martina, Luksić / Metelko, Zeljko / Mirosević, Gorana / Vrbica, Sanja Mlinaric / Renar, Ivana Pavlić / Petric, Dragomir / Prasek, Manja / Prpić-Kizevać, Ivana / Radman, Maja / Soldo, Dragan / Sarić, Tereza / Tesanović, Sandi / Kurir, Tina Ticinovic / Wensveen, Tamara Turk / Botica, Marija / Vrkljan, Milan / Rotkvic, Vanja Zjacić / Zorić, Cedomir / Krznarić, Zeljko. · ·Lijec Vjesn · Pubmed #27443001.

ABSTRACT: INTRODUCTION: The Croatian Association for Diabetes and Metabolic Disorders of the Croatian Medical Association has issued in 2011 the first national guidelines for the nutrition, education, self-control, and pharmacotherapy of diabetes type 2. According to the increased number of available medicines and new evidence related to the effectiveness and safety of medicines already involved in the therapy there was a need for update of the existing guidelines for the pharmacotherapy of type 2 diabetes in the Republic of Croatia. PARTICIPANTS: as co-authors of the Guidelines there are listed all members of the Croatian Association for Diabetes and Metabolic Diseases, as well as other representatives of professional societies within the Croatian Medical Association, who have contributed with comments and suggestions to the development of the Guidelines. EVIDENCE: These guidelines are evidence-based, according to the GRADE system (eng. Grading of Recommendations, Assessment, Development and Evaluation), which describes the level of evidence and strength of recommendations. CONCLUSIONS: An individual patient approach based on physiological principles in blood glucose control is essential for diabetes' patients management. Glycemic targets and selection of the pharmacological agents should be tailored to the patient, taking into account the age, duration of disease, life expectancy, risk of hypoglyce- mia, comorbidities, developed vascular and other complications as well as other factors. Because of all this, is of national interest to have a practical, rational and applicable guidelines for the pharmacotherapy of type 2 diabetes.

24 Guideline Treatment of Type 2 Diabetes: From "Guidelines" to "Position Statements" and Back: Recommendations of the Israel National Diabetes Council. 2016

Mosenzon, Ofri / Pollack, Rena / Raz, Itamar. ·Diabetes Unit, Division of Internal Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel. · Diabetes Unit, Division of Internal Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel ntv502@netvision.net.il. ·Diabetes Care · Pubmed #27440827.

ABSTRACT: Given the increased prevalence of type 2 diabetes worldwide, most patients are treated by their primary health care team (PHCT). PHCTs need guidance in choosing the best treatment regimen for patients, since the number of glucose-lowering agents (GLAs) is rapidly increasing, as is the amount of clinical data regarding these drugs. The American Diabetes Association/European Association for the Study of Diabetes Position Statement emphasizes the importance of personalized treatment and lists drug efficacy, risk of hypoglycemia, effect on weight, side effects, and cost as important parameters to consider when choosing GLAs. The suggested Israeli guidelines refocus earlier international recommendations from 2012 and 2015, based on emerging data from cardiovascular outcome trials as well as what we believe are important issues for patient care (i.e., durability, hypoglycemia risk, and weight gain).

25 Guideline The Role of Interventional Radiology in the Treatment of Arterial Diabetic Foot Disease. 2016

Reekers, Jim A. ·Department of Radiology, G1.206, Academic Medical Center, University of Amsterdam, Meibergdreef 9, PO Box 22660, 1100 DD, Amsterdam, The Netherlands. j.a.reekers@amc.uva.nl. ·Cardiovasc Intervent Radiol · Pubmed #27435578.

ABSTRACT: -- No abstract --

Next